Tongjitang Chinese Medicines Company is a vertically integrated and profitable specialty pharmaceutical company focusing on the development, manufacturing,marketing and selling of modernized traditional Chinese medicine in China.

Its flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi amounts. In addition to Xianling Gubao, the company manufactures and markets 36 other modernized traditional Chinese medicine products and 37western drugs.

Established in 1995, Tongjitang conducts substantially all of its business through operating subsidiarier in China -- Tongjitang Pharmaceutical Co.,Ltd, Tongjitang Distribution Co.,Ltd, Tongjitang Chain Stores Co.,Ltd, Guizhou LLF Pharmaceutical Co., Ltd, Qinghai Pulante Pharmaceutical Co. Ltd and Anhui Jingfang Pharmaceutical Co. Ltd.

In March 2007, Tongjitang became the first ever traditional Chinese medicine company completing an IPO at NYSE.